Cell cycle inhibition without disruption of neurogenesis is a strategy for treatment of aberrant cell cycle diseases: An update

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

Since publishing our earlier report describing a strategy for the treatment of central nervous system (CNS) diseases by inhibiting the cell cycle and without disrupting neurogenesis (Liu et al. 2010), we now update and extend this strategy to applications in the treatment of cancers as well. Here, we put forth the concept of aberrant cell cycle diseases to include both cancer and CNS diseases, the two unrelated disease types on the surface, by focusing on a common mechanism in each aberrant cell cycle reentry. In this paper, we also summarize the pharmacological approaches that interfere with classical cell cycle molecules and mitogenic pathways to block the cell cycle of tumor cells (in treatment of cancer) as well as to block the cell cycle of neurons (in treatment of CNS diseases). Since cell cycle inhibition can also block proliferation of neural progenitor cells (NPCs) and thus impair brain neurogenesis leading to cognitive deficits, we propose that future strategies aimed at cell cycle inhibition in treatment of aberrant cell cycle diseases (i.e., cancers or CNS diseases) should be designed with consideration of the important side effects on normal neurogenesis and cognition.

Original languageEnglish (US)
Article number491737
JournalThe Scientific World Journal
Volume2012
DOIs
StatePublished - May 21 2012

Fingerprint

Neurogenesis
Cell Cycle
Cells
nervous system
Central Nervous System Diseases
cancer
Neurology
Neoplasms
cognition
Inhibition (Psychology)
tumor
brain
Reentry
Cognition
Neurons
Stem Cells
Tumors
Brain
Pharmacology
Molecules

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Environmental Science(all)

Cite this

@article{b4c67e905dff4ce186ebca2af83b2a20,
title = "Cell cycle inhibition without disruption of neurogenesis is a strategy for treatment of aberrant cell cycle diseases: An update",
abstract = "Since publishing our earlier report describing a strategy for the treatment of central nervous system (CNS) diseases by inhibiting the cell cycle and without disrupting neurogenesis (Liu et al. 2010), we now update and extend this strategy to applications in the treatment of cancers as well. Here, we put forth the concept of aberrant cell cycle diseases to include both cancer and CNS diseases, the two unrelated disease types on the surface, by focusing on a common mechanism in each aberrant cell cycle reentry. In this paper, we also summarize the pharmacological approaches that interfere with classical cell cycle molecules and mitogenic pathways to block the cell cycle of tumor cells (in treatment of cancer) as well as to block the cell cycle of neurons (in treatment of CNS diseases). Since cell cycle inhibition can also block proliferation of neural progenitor cells (NPCs) and thus impair brain neurogenesis leading to cognitive deficits, we propose that future strategies aimed at cell cycle inhibition in treatment of aberrant cell cycle diseases (i.e., cancers or CNS diseases) should be designed with consideration of the important side effects on normal neurogenesis and cognition.",
author = "Da Liu and Bradley Ander",
year = "2012",
month = "5",
day = "21",
doi = "10.1100/2012/491737",
language = "English (US)",
volume = "2012",
journal = "The Scientific World Journal",
issn = "2356-6140",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Cell cycle inhibition without disruption of neurogenesis is a strategy for treatment of aberrant cell cycle diseases

T2 - An update

AU - Liu, Da

AU - Ander, Bradley

PY - 2012/5/21

Y1 - 2012/5/21

N2 - Since publishing our earlier report describing a strategy for the treatment of central nervous system (CNS) diseases by inhibiting the cell cycle and without disrupting neurogenesis (Liu et al. 2010), we now update and extend this strategy to applications in the treatment of cancers as well. Here, we put forth the concept of aberrant cell cycle diseases to include both cancer and CNS diseases, the two unrelated disease types on the surface, by focusing on a common mechanism in each aberrant cell cycle reentry. In this paper, we also summarize the pharmacological approaches that interfere with classical cell cycle molecules and mitogenic pathways to block the cell cycle of tumor cells (in treatment of cancer) as well as to block the cell cycle of neurons (in treatment of CNS diseases). Since cell cycle inhibition can also block proliferation of neural progenitor cells (NPCs) and thus impair brain neurogenesis leading to cognitive deficits, we propose that future strategies aimed at cell cycle inhibition in treatment of aberrant cell cycle diseases (i.e., cancers or CNS diseases) should be designed with consideration of the important side effects on normal neurogenesis and cognition.

AB - Since publishing our earlier report describing a strategy for the treatment of central nervous system (CNS) diseases by inhibiting the cell cycle and without disrupting neurogenesis (Liu et al. 2010), we now update and extend this strategy to applications in the treatment of cancers as well. Here, we put forth the concept of aberrant cell cycle diseases to include both cancer and CNS diseases, the two unrelated disease types on the surface, by focusing on a common mechanism in each aberrant cell cycle reentry. In this paper, we also summarize the pharmacological approaches that interfere with classical cell cycle molecules and mitogenic pathways to block the cell cycle of tumor cells (in treatment of cancer) as well as to block the cell cycle of neurons (in treatment of CNS diseases). Since cell cycle inhibition can also block proliferation of neural progenitor cells (NPCs) and thus impair brain neurogenesis leading to cognitive deficits, we propose that future strategies aimed at cell cycle inhibition in treatment of aberrant cell cycle diseases (i.e., cancers or CNS diseases) should be designed with consideration of the important side effects on normal neurogenesis and cognition.

UR - http://www.scopus.com/inward/record.url?scp=84861063454&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861063454&partnerID=8YFLogxK

U2 - 10.1100/2012/491737

DO - 10.1100/2012/491737

M3 - Review article

C2 - 22547985

AN - SCOPUS:84861063454

VL - 2012

JO - The Scientific World Journal

JF - The Scientific World Journal

SN - 2356-6140

M1 - 491737

ER -